<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04850625</url>
  </required_header>
  <id_info>
    <org_study_id>YOUNGBC-14</org_study_id>
    <nct_id>NCT04850625</nct_id>
  </id_info>
  <brief_title>Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine</brief_title>
  <official_title>Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: a Multicenter, Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective study aiming to explore the efficacy and safety of Pyrotinib plus&#xD;
      Vinorelbine versus Lapatinib plus Capecitabine in patients with previously treated&#xD;
      HER2-positive metastatic breast cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2020</start_date>
  <completion_date type="Actual">June 15, 2021</completion_date>
  <primary_completion_date type="Actual">June 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>6 weeks</time_frame>
    <description>Progression free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">224</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Pyrotinib Plus Vinorelbine</arm_group_label>
    <description>lapatinib (750-1,250 mg/day) plus capecitabine (1,500-2,000 mg/m2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lapatinib Plus Capecitabine</arm_group_label>
    <description>pyrotinib (320-400 mg/day) plus vinorelbine (25mg/ m2 intravenously or 60 mg/m2 orally on days 1 and 8 per 21 days)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with breast cancer (according to ICD-10) with confirmed metastasis,&#xD;
        regardless of being de novo diagnosed or progressed from a non-metastatic stage&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HER2+ MBC patients scored +3 by immunohistochemical (IHC) analysis or scored +2 and&#xD;
             the result of fluorescence in situ hybridization was positive.&#xD;
&#xD;
          -  Patients were previously treated with trastuzumab in the advanced setting and a taxane&#xD;
             in any setting.&#xD;
&#xD;
          -  Patients received lapatinib (750-1,250 mg/day) plus capecitabine (1,500-2,000 mg/m2)&#xD;
             or pyrotinib (320-400 mg/day) plus vinorelbine (25mg/ m2 intravenously or 60 mg/m2&#xD;
             orally on days 1 and 8 per 21 days) for at least one cycle, starting from Jun 2015 to&#xD;
             Jan 2021.&#xD;
&#xD;
          -  Patients had complete medical records. All data were retrospectively collected from&#xD;
             medical records of individual institutions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Incomplete medical history&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biyun Wang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Biyun Wang, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pyrotinib</keyword>
  <keyword>Lapatinib</keyword>
  <keyword>Vinorelbine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

